CD274 and colorectal cancer: Also, FPs targeting lipopolysaccharide, which is one of the most prevalent products in the gut microbiome and is associated with low rates of response to anti–PD-L1 ICIs, significantly improved the efficacy of anti–PD-L1 immunotherapy in patients with colorectal cancer (18).